Moreover, FGF21 as a potential biomarker of non-alcoholic-fatty-liver disease (NAFLD) may play a role in hepatic lipid metabolism as its serum concentration is elevated in NAFLD and its expression correlates positively with liver steatosis [20]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.